Table I

Clinical and pathological information of serum samples used for training and validation assays. B, Bellvitge University Hospital, Institut Catalá d́Oncología (Barcelona, Spain); PH, Puerta de Hierro Hospital (Madrid, Spain), C, Cabueñes Hospital (Gijón, Spain)

GenderDukes stage
Number (n)HospitalAge average (years)Age range (years)MaleFemaleABCD
TotalCRC6569.741–9167.7%33.3%19%22%29%30%
Controls11868.426–8961.5%38.5%
Microarray screeningCRC15B66.254–8273%27%40%20%20%20%
Healthy15B63.539–8960%40%
ValidationCRC50B, PH70.841–9166%34%12%22%32%34%
Controls103B, PH, C59.226–8951%49%
    Healthy46B, PH, C59.634–8963%37%
    CRC familiar antecedents10C49.426–7325%75%
    Ulcerative colitis2C3928–4950%50%
    Hyperplasic polyp2C6761–7350%50%
    Other tumors
        Bladder cancer11B67.758–7864%36%
        Breast cancer8B5230–660%100%
        Lung cancer8B6355–7775%25%
        Pancreas cancer8B6537–7462%38%
        Stomach cancer8B6237–8025%75%